Scarica l'app Stockscreener
1.67
4.57%
-0.08
Dopo l'orario di chiusura:
1.72
0.05
+2.99%
Precedente Chiudi:
$1.75
Aprire:
$1.75
Volume 24 ore:
245.82K
Relative Volume:
0.32
Capitalizzazione di mercato:
$71.48M
Reddito:
-
Utile/perdita netta:
$-77.27M
Rapporto P/E:
-0.8342
EPS:
-2.0019
Flusso di cassa netto:
$-66.29M
1 W Prestazione:
+4.37%
1M Prestazione:
-12.57%
6M Prestazione:
-29.24%
1 anno Prestazione:
+42.74%
Intervallo 1D:
$1.67
$1.795
Intervallo di 1 settimana:
$1.62
$1.90
Portata 52W:
$1.05
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.67 | 74.90M | 0 | -77.27M | -66.29M | -2.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move - Stock Titan
ACRV Stock Price, Quote & Chart | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline By Investing.com - Investing.com Australia
Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit - Quiver Quantitative
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - The Manila Times
Acrivon CEO to join TD Cowen cancer innovation webcast May 26 - Stock Titan
9,366 RSUs granted to Acrivon (ACRV) director for RA Capital funds - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units as equity award - Stock Titan
Director at Acrivon Therapeutics (ACRV) awarded 9,366 RSUs vesting 2027 - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs vesting in 2027 - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CFO awarded 46,167 RSUs, holdings rise to 67,150 shares - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs award - Stock Titan
Acrivon Therapeutics (ACRV) director granted 9,366 restricted stock units - Stock Titan
Acrivon Therapeutics (ACRV) CAO awarded 14,227 RSUs in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CMO receives 38,817-share restricted stock unit grant - Stock Titan
Acrivon Therapeutics (ACRV) grants 49,830 RSUs to Chief Legal Officer Mary Miller - Stock Titan
Acrivon Therapeutics (ACRV) CDO receives 38,584-share RSU grant with staged vesting - Stock Titan
Acrivon (ACRV) COO Eric Devroe receives 72,981 RSU stock grant - Stock Titan
Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants - Stock Titan
ACRV News | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock - simplywall.st
Acrivon (NASDAQ: ACRV) CLO has 184 shares withheld for RSU tax - Stock Titan
Acrivon Therapeutics (ACRV) CAO reports 99-share tax withholding on RSU vesting - Stock Titan
Acrivon (ACRV) CDO has 404 shares withheld to cover RSU tax liability - Stock Titan
[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity - Stock Titan
Acrivon (NASDAQ: ACRV) leaders use 1,743 shares for RSU tax withholding - Stock Titan
Maxim Group Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy - TipRanks
Number of shareholders of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Citadel affiliates disclose 13‑share stake in Acrivon (NASDAQ: ACRV) - Stock Titan
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer - The Globe and Mail
Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress By Investing.com - Investing.com Australia
Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress - Investing.com
H.C. Wainwright Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials - TipRanks
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts - Sahm
Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M - TradingView
Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Acrivon Therapeutics Q1 Loss Narrows - Moomoo
Acrivon Therapeutics Q1 net loss narrows - TradingView
Biotech Acrivon has cash to advance cancer drugs into Q3 2027 - Stock Titan
Acrivon Therapeutics (NASDAQ: ACRV) posts Q1 loss and extends cash runway - Stock Titan
Acrivon (Nasdaq: ACRV) posts Q1 2026 loss and extends cash runway - Stock Titan
The strategic moves Acrivon (ACRV) is making now (-1.26%) 2026-05-11Bullish Pattern - newser.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MSN Money - MSN
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acrivon Therapeutics Inc Azioni (ACRV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levy Adam D. | Chief Financial Officer |
Jan 14 '26 |
Buy |
1.70 |
8,832 |
14,999 |
20,983 |
| Devroe Eric | Chief Operating Officer |
Jan 13 '26 |
Buy |
1.72 |
10,000 |
17,218 |
75,308 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):